Nature Communications (Jan 2017)
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
- Renea A. Taylor,
- Michael Fraser,
- Julie Livingstone,
- Shadrielle Melijah G. Espiritu,
- Heather Thorne,
- Vincent Huang,
- Winnie Lo,
- Yu-Jia Shiah,
- Takafumi N. Yamaguchi,
- Ania Sliwinski,
- Sheri Horsburgh,
- Alice Meng,
- Lawrence E. Heisler,
- Nancy Yu,
- Fouad Yousif,
- Melissa Papargiris,
- Mitchell G. Lawrence,
- Lee Timms,
- Declan G. Murphy,
- Mark Frydenberg,
- Julia F. Hopkins,
- Damien Bolton,
- David Clouston,
- John D. McPherson,
- Theodorus van der Kwast,
- Paul C. Boutros,
- Gail P. Risbridger,
- Robert G. Bristow
Affiliations
- Renea A. Taylor
- Department of Physiology, Monash Partners Comprehensive Cancer Consortium and Cancer Program, Biomedicine Discovery Institute, Monash University
- Michael Fraser
- Princess Margaret Cancer Centre, University Health Network
- Julie Livingstone
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Shadrielle Melijah G. Espiritu
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Heather Thorne
- Research Department, kConFab, Peter MacCallum Cancer Centre
- Vincent Huang
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Winnie Lo
- Princess Margaret Cancer Centre, University Health Network
- Yu-Jia Shiah
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Takafumi N. Yamaguchi
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Ania Sliwinski
- The Sir Peter MacCallum Department of Oncology University of Melbourne
- Sheri Horsburgh
- Princess Margaret Cancer Centre, University Health Network
- Alice Meng
- Princess Margaret Cancer Centre, University Health Network
- Lawrence E. Heisler
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Nancy Yu
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Fouad Yousif
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Melissa Papargiris
- Department of Anatomy and Developmental Biology, Monash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
- Mitchell G. Lawrence
- Department of Anatomy and Developmental Biology, Monash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
- Lee Timms
- Genome Technologies Program, Ontario Institute for Cancer Research
- Declan G. Murphy
- Department of Cancer Surgery, Peter MacCallum Cancer Centre
- Mark Frydenberg
- Department of Anatomy and Developmental Biology, Monash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
- Julia F. Hopkins
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Damien Bolton
- Department of Anatomy and Developmental Biology, Monash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
- David Clouston
- Urological Pathology, Tissupath
- John D. McPherson
- Genome Technologies Program, Ontario Institute for Cancer Research
- Theodorus van der Kwast
- Princess Margaret Cancer Centre, University Health Network
- Paul C. Boutros
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research
- Gail P. Risbridger
- Department of Anatomy and Developmental Biology, Monash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Monash University
- Robert G. Bristow
- Princess Margaret Cancer Centre, University Health Network
- DOI
- https://doi.org/10.1038/ncomms13671
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 10
Abstract
Men that carrierBRCA2germline mutations are at risk of developing prostate cancer. Here, the authors analyse the genomes of prostate cancer from these individuals and demonstrate increased genomic instability in comparison to sporadic prostate cancer.
